Masateru Ushio
Shiga University of Medical Science
SteatosisNonalcoholic fatty liver diseaseEzetimibeFatty liverIntestinal cholesterol absorption
What is this?
Publications 1
#1Masateru Ushio (Shiga University of Medical Science)H-Index: 1
#2Yoshihiko Nishio (Kadai: Kagoshima University)H-Index: 20
Last. Hiroshi Maegawa (Shiga University of Medical Science)H-Index: 49
view all 11 authors...
Nonalcoholic fatty liver disease is the most frequent liver disease. Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been reported to ameliorate hepatic steatosis in human and animal models. To explore how ezetimibe reduces hepatic steatosis, we investigated the effects of ezetimibe on the expression of lipogenic enzymes and intestinal lipid metabolism in mice fed a high-fat or a high-fructose diet. CBA/JN mice were fed a high-fat diet or a high-fructose diet for 8 wk with or w...
26 CitationsSource